Calendar of Events
- February 22-24
- SECO, Atlanta, Ga
- March 23 - 25
- International Vision Expo, New York, NY
- April 11-14
- American Academy of Managed Care, San Diego, Calif
- June 23-26
- NACDS, Boston, Mass
- June 27 - July 1
- American Optometric Association, Boston, Mass
- August 5-9
- National Conference of State Legislaturers, Boston, Mass
- October 4-6
- International Vision Expo, Las Vegas, Nev
- October 24-27
- American Academy of Optometry, Tampa, Fla
- November 10-13
- American Academy of Ophthalmology, New Orleans, La
2007 Events
© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.
RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.
The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.